Challenges and opportunities in PV
| . | Challenge . | Opportunity . |
|---|---|---|
| Quantity | Educate patients and doctors about latency and dynamic nature of disease | Understand the role of JAK2V617F VAF as a diagnostic and prognostic marker |
| Meaningful cytoreduction without toxicity | ||
| Quality | Understand mechanism in which JAK2V617F alters cell function | Design and use medications that will reform cell function and reduce thrombosis risk |
| Understand methods of thrombosis risk reduction | ||
| Clonal expansion | Scientific underpinning of latent and dynamic disease owing to the clonal nature of JAK2V617F | Design trials and drugs to address clonal expansion |
| Study mechanisms underlying both latency and clonal expansion |
| . | Challenge . | Opportunity . |
|---|---|---|
| Quantity | Educate patients and doctors about latency and dynamic nature of disease | Understand the role of JAK2V617F VAF as a diagnostic and prognostic marker |
| Meaningful cytoreduction without toxicity | ||
| Quality | Understand mechanism in which JAK2V617F alters cell function | Design and use medications that will reform cell function and reduce thrombosis risk |
| Understand methods of thrombosis risk reduction | ||
| Clonal expansion | Scientific underpinning of latent and dynamic disease owing to the clonal nature of JAK2V617F | Design trials and drugs to address clonal expansion |
| Study mechanisms underlying both latency and clonal expansion |